
Can treating cancer directly at the tumor site change how we approach difficult-to-treat solid tumors? Our CEO Lew Bender was featured in @digitaljournal, discussing how investigational INT230-6 is designed to attack tumors directly while stimulating a broader immune response. From a 75% disease control rate in our Phase 1/2 monotherapy study to promising preliminary INVINCIBLE-4 data, Lew shares how we're exploring new approaches to treating difficult-to-treat solid tumors. 🔗 Read the full Q&A: digitaljournal.com/article/q…


















